Cough
Drug research and approvals for cough: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 87 studies of cough are recruiting on ClinicalTrials.gov, Health Canada has authorized 19 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 87
- Trials authorized in Canada: 19
- FDA orphan approvals: 0
- EU medicines: 2
Recruiting Now
Newest start dates first, of 87 recruiting on ClinicalTrials.gov ↗- Effect of Targeted Tracheal Kinesio Taping on Cough Efficacy and Decannulation Time in Burned PatientsNCT07932509 · Not applicable · MTI University · starts Nov 10, 2026
- Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in…NCT07566117 · Not applicable · University of North Carolina, Chapel Hill · starts Nov 9, 2026
- Feasibility of Cough Skill Training in Individuals With Head and Neck CancerNCT07756684 · Not applicable · Boston University Charles River Campus · starts Oct 28, 2026
- Study of BK1803 in Healthy InfantsNCT07793513 · Phase 3 · Tanabe Pharma Corporation · starts Oct 21, 2026
- A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated…NCT07891104 · Phase 1 / Phase 2 · Institute of Medical Biology, Chinese Academy of Medical Sciences · starts Oct 11, 2026
- Remifentanil Versus Remifentanil-Lidocaine for Tracheal Extubation After ThyroidectomyNCT07857356 · Phase 4 · Pamukkale University · starts Oct 1, 2026
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsNCT07868419 · Phase 3 · Trevi Therapeutics · starts Sep 30, 2026
- Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic CoughNCT06960759 · Phase 2 · University of Montana · starts Aug 13, 2026
- A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For…NCT07894055 · Phase 2 · Changchun BCHT Biotechnology Co. · starts Aug 12, 2026
- Dose-Escalation Study of Artesunate Patients With IPFNCT05988463 · Phase 1 · Joseph C. Wu · starts Aug 1, 2026
Drug Pipeline
20 approved, 14 in phase 3, 32 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Gefapixant, Guaifenesin, Benzonatate, Codeine, Diphenhydramine, Dextromethorphan, Pseudoephedrine, Menthol, Camphor, Hydrocodone, Pholcodine, Zipeprol, Oxeladin, Clobutinol, Chlorpheniramine, Brompheniramine, Phenylephrine, Chlophedianol, Noscapine, Isoaminile
- Lidocaine
- Phase 3 Sodium channel alpha subunit blocker
- Azithromycin
- Phase 3 Bacterial 70S ribosome inhibitor
- Syrup
- Phase 3
- Guaiacol
- Phase 3
- Bupivacaine
- Phase 3 Sodium channel protein type IV alpha subunit blocker
- Thalidomide
- Phase 3 CRL4(CRBN) E3 ubiquitin ligase inhibitor
- Ranitidine
- Phase 3 Histamine H2 receptor antagonist
- Triamcinolone acetonide
- Phase 3 Glucocorticoid receptor agonist
- Omeprazole
- Phase 3 Potassium-transporting ATPase inhibitor
- Eucalyptol
- Phase 3
- Dropropizine
- Phase 3
- Oxomemazine
- Phase 3
- Levodropropizine
- Phase 3
- Oxolamine
- Phase 3
- Camlipixant
- Phase 2 P2X purinoceptor 3 antagonist
- SCH-486757
- Phase 2 Nociceptin receptor agonist
- Eliapixant
- Phase 2
- Albuterol
- Phase 2 Beta-2 adrenergic receptor agonist
- Montelukast
- Phase 2 Cysteinyl leukotriene receptor 1 antagonist
- Levocetirizine
- Phase 2 Histamine H1 receptor antagonist
- Orvepitant
- Phase 2 Neurokinin 1 receptor antagonist
- Bradanicline
- Phase 2 Neuronal acetylcholine receptor protein alpha-7 subunit agonist
- Indantadol
- Phase 2 Glutamate [NMDA] receptor antagonist
- XEN-D0501
- Phase 2 Vanilloid receptor antagonist
- Zinc acetate anhydrous
- Phase 2 Skin protectant
- Ambroxol
- Phase 2
- Capsicum oleoresin
- Phase 2
- GSK-2339345
- Phase 2
- Carbetapentane
- Phase 2 Sigma opioid receptor agonist
- Dibunic acid
- Phase 2
Showing the 30 furthest along of 52 in trials.
How Its Trials Ended
295 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 69 whose ending is known, 59% met their primary endpoint, 10% missed it and 30% stopped early.
- Completed, result not reported12542%
- Status unknown5519%
- Ongoing4616%
- Met its primary endpoint4114%
- Stopped: other or unclear93%
- Missed its primary endpoint72%
- Stopped: lack of efficacy62%
- Stopped: enrollment or feasibility62%
Trials Authorized in Canada
The 10 newest of 19; search them all in Canada trials| Sep 28, 2026 | A randomized, double-blind, placebo-controlled twelve-week fixed-dose study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the…Nalbuphine | Trevi Therapeutics Inc | Pending |
| May 22, 2026 | A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the treatment…Nalbuphine | Trevi Therapeutics Inc | Ongoing |
| Nov 27, 2025 | A 2x2 factorial, randomized, open-label trial to evaluate neuromodulators and cough control therapy in patients with refractory or unexplained chronic cough:…Morphine / pregabalin | Mcmaster University | Pending |
| Sep 3, 2025 | Understanding the role of airway mucus occlusions in canadians with asthma, copd and chronic cough (canmuc)Hyperpolarized XENON-129 | Mcmaster University | Pending |
| Jun 30, 2025 | Assessing the efficacy of novel nasopharyngeal delivery system in alleviating post-nasal drip: a pilot studyCiclesonide | Research Institute Of The Mcgill University Health Centre | Pending |
| Feb 11, 2025 | A phase 3, 24-week, randomized, double-blind, placebo-controlled, parallelarm efficacy and safety study with open-label extension of blu-5937 in adult…Camlipixant (GSK5464714, BLU-5937) | Bellus Health Inc | Ongoing |
| Sep 26, 2024 | A phase 2b, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of taplucainium inhalation powder (noc-110) in…Taplucainium (NOC-110/NTX-1175) | Nocion Therapeutics, Inc | Ongoing |
| Aug 21, 2023 | A randomized, double-blind, placebo-controlled, parallel, 4-arm dose ranging study of the safety and efficacy of nal er tablets for the treatment of cough in…Nalbuphine | Trevi Therapeutics Inc | Closed |
| Aug 11, 2023 | A phase 2, double-blind, randomized, placebo-controlled, two-period crossover efficacy and safety study of nalbuphine er tablets for the treatment of…Nalbuphine | Trevi Therapeutics Inc | Closed |
| Nov 16, 2022 | A phase 3, 52-week, randomized, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of blu-5937 in adult…Camlipixant (BLU-5937) | Bellus Health Inc | Closed |
Medicines Authorised in the EU
Newest first| Jan 9, 2026 | VacPertagenPertussis vaccine (recombinant, acellular, component, adsorbed) | BioNet Europe | EMA ↗ |
| Sep 15, 2023 | LyfnuaGefapixant | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA